Neuroinflammation, the accompanying amyloid plaque
Post# of 145754
![](/assets/46931549/no_avatar_available_thumb.jpg)
CCL5 does have a protective benefit by mediating glutamate release. CCR5 is the predominate receptor, CCL5 also binds to CCR1 and CCR3. CCR1, CCR3 and GPR75 have a lesser binding affinity for CCR5 and are expressed at a much lower level than CCR5. Thus you have a low level of CCL5 activity that allows neuroprotective glutamate mediation without the damaging inflammation.
With MCP-1 (CCL2) that is mentioned in the article which is neuroprotective (and also helps kill tumor cells) that binds to CCR2 so CCR5 blockade is not an issue.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)